Cancer Immunotherapy Market | Top Key Players - F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, GlaxoSmithKline Plc., Amgen Inc., Bristol-Myers Squibb, ELI Lilly

The market for cancer immunotherapy across the globe is expected growth at a very high rate in the coming future. The growth is attributed to an increase number of patients suffering from different types of cancer. Globally nearly 100 types of different types of cancer have been registered. However, in terms of treatment, limited number of treatments are available in the market.

Cancer immunotherapy is expected to make a huge development in coming future due to its various advantages. Immunotherapy is found to be more effective than other available therapies and have lesser side effects. Increasing population diagnosed with cancer across the globe is a direct consequence of the lowering health standards i.e. increasing smoking and alcohol intake in millennial population has led to an increase in the number of lung and liver cancers, thereby fuelling the growth of the market. Various factors affecting the market growth are long time for approval, high cost of treatment and many adverse effects may hinder the market growth.

Get a sample report at https://www.marketresearchfuture.com/sample_request/567 .

F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis AG, GlaxoSmithKline Plc., Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. are some of the leading players at the cutting edge of the competition in the market of cancer immunotherapy across the globe.

Key developments

Key players in the market are engaged in the development of new products to capture the market globally. Therefore, key market players are investing more in research and development activity, in order to lead the global market. In this regards, market players undertake various strategic approaches.

Pfizer Inc.

Pfizer Inc. is a major research based bio pharmaceutical organization. The company manufactures medicines and vaccines that help individuals in their disease condition and keep them from becoming sick in any case.

In August, 2016, the company announced the approval of FDA approval TROXYCA ER extended-release capsules CII for pain management. The drug is used for abuse-deterrent properties for the management of pain and will help Pfizer to improve their goodwill and sales with this new product

In July 2016, Bind Therapeutics entered in an asset purchase agreement with Pfizer Inc. Bind Therapeutics Inc. entered into an asset purchase agreement with Pfizer, Inc. On July 26, 2016, company amended the stalking horse agreement. The acquisition is expected to close on or about August 1, 2016.

In July 2016, Pfizer and Western Oncolytics announce immuno-oncology research collaboration. This collaboration has the aim to investigate novel oncolytic virus technology. Both, Pfizer and Western Oncolytics are expected to collaborate on preclinical, clinical development of WO-12 through Phase I trials. Financial terms of agreement are not disclosed

June 2016: Pfizer announced the completion of acquisition of Anacor Pharmaceuticals. This acquisition will help the company to accelerate their shared commitment to help patients with inflammatory disease, an area of high unmet medical need

More inquire at https://www.marketresearchfuture.com/enquiry/567 .

Merck:

January, 2017: BioControl was acquired by Pfizer to strengthen position in food safety testing

August, 2012: Biochrom AG, cell culture media specialist was acquired by Merck.

Novartis

In March 2016, cancer drug by Novartis gets FDA's principal 'biosimilar' affirmation. Federal regulators have allowed the first “biosimilar” drug to be sold in the U.S. under a program intended to branch a new market of lower-cost substitutes to some of the most expensive treatments in healthcare. The approval of biosimilars will help many patients who are in need of these treatments. 

In May 2016, Novartis studied new sales model for tentative cancer therapy. Novartis strategies to use a medical device-like sales model to market its CAR T-cell technology if the new cancer treatment receives FDA approval. This methodology may help stem concern about the therapy's complex distribution process as well as the expected high prices for treatment.

F. Hoffmann-La Roche AG:

In August, 2015: GeneWEAVE was acquired by F. Hoffmann-La Roche AG to strengthen offerings in microbiology diagnostics. Roche will pay GeneWEAVE shareholders USD 190 million upfront and up to USD 235 million in contingent product related milestones

In February 2015, F. Hoffmann-La Roche AG together with BioMed X announced the collaboration for the development of Nanomaterial-Based Biosensors for Near-Patient Testing

September 2014: Elecsys anti-Müllerian Hormone (AMH) fertility test was launched by F. Hoffmann-La Roche AG for assessment of ovarian reserve for pregnancy

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312

W: www.marketresearchfuture.com

sales@marketresearchfuture.com

This release was published on openPR.